JP2012522802A5 - - Google Patents

Download PDF

Info

Publication number
JP2012522802A5
JP2012522802A5 JP2012503723A JP2012503723A JP2012522802A5 JP 2012522802 A5 JP2012522802 A5 JP 2012522802A5 JP 2012503723 A JP2012503723 A JP 2012503723A JP 2012503723 A JP2012503723 A JP 2012503723A JP 2012522802 A5 JP2012522802 A5 JP 2012522802A5
Authority
JP
Japan
Prior art keywords
conjugate
composition
antigen
hyperbranched polymer
helper peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012503723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012522802A (ja
JP5661735B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/029694 external-priority patent/WO2010115046A2/en
Publication of JP2012522802A publication Critical patent/JP2012522802A/ja
Publication of JP2012522802A5 publication Critical patent/JP2012522802A5/ja
Application granted granted Critical
Publication of JP5661735B2 publication Critical patent/JP5661735B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012503723A 2009-04-01 2010-04-01 ワクチン組成物及びその使用方法 Expired - Fee Related JP5661735B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16573209P 2009-04-01 2009-04-01
US61/165,732 2009-04-01
PCT/US2010/029694 WO2010115046A2 (en) 2009-04-01 2010-04-01 Vaccine compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014243829A Division JP2015096520A (ja) 2009-04-01 2014-12-02 ワクチン組成物及びその使用方法

Publications (3)

Publication Number Publication Date
JP2012522802A JP2012522802A (ja) 2012-09-27
JP2012522802A5 true JP2012522802A5 (https=) 2013-05-23
JP5661735B2 JP5661735B2 (ja) 2015-01-28

Family

ID=42828943

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2012503723A Expired - Fee Related JP5661735B2 (ja) 2009-04-01 2010-04-01 ワクチン組成物及びその使用方法
JP2014243829A Pending JP2015096520A (ja) 2009-04-01 2014-12-02 ワクチン組成物及びその使用方法
JP2016105809A Expired - Fee Related JP6139000B2 (ja) 2009-04-01 2016-05-27 ワクチン組成物及びその使用方法
JP2017086900A Expired - Fee Related JP6321261B2 (ja) 2009-04-01 2017-04-26 ワクチン組成物及びその使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014243829A Pending JP2015096520A (ja) 2009-04-01 2014-12-02 ワクチン組成物及びその使用方法
JP2016105809A Expired - Fee Related JP6139000B2 (ja) 2009-04-01 2016-05-27 ワクチン組成物及びその使用方法
JP2017086900A Expired - Fee Related JP6321261B2 (ja) 2009-04-01 2017-04-26 ワクチン組成物及びその使用方法

Country Status (9)

Country Link
US (2) US9764012B2 (https=)
EP (1) EP2413964B1 (https=)
JP (4) JP5661735B2 (https=)
CN (2) CN107050440B (https=)
AU (1) AU2010232512B2 (https=)
BR (1) BRPI1016133A2 (https=)
CA (1) CA2756996C (https=)
RU (2) RU2600798C2 (https=)
WO (1) WO2010115046A2 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2709176T3 (es) 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
EP2247306B1 (en) 2008-02-14 2018-04-18 Life Sciences Research Partners VZW Immunogenic control of tumours and tumour cells
US9764012B2 (en) 2009-04-01 2017-09-19 University Of Miami Vaccine compositions and methods of use thereof
ES2731343T3 (es) * 2009-05-19 2019-11-15 Univ Miami Composiciones, kits y métodos para presentación de antígenos in vitro, evaluación de eficacia de vacunas y evaluación de la inmunotoxicidad de productos biológicos y fármacos
CA2762653A1 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
AU2011258165B2 (en) 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
IN2014MN00433A (https=) * 2011-09-07 2015-06-19 Midatech Ltd
AU2012306258A1 (en) * 2011-09-07 2014-04-17 Immunotope, Inc. Nanoparticle tumour vaccines
GB201201511D0 (en) * 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
WO2014120804A1 (en) * 2013-01-30 2014-08-07 University Of Miami Enteric coated nanoparticles for oral vaccine and drug delivery and methods of production and use thereof
US20140220079A1 (en) * 2013-02-05 2014-08-07 Nitto Denko Corporation Vaccine composition for mucosal administration
EP2762158A1 (en) * 2013-02-05 2014-08-06 Nitto Denko Corporation E75-vaccine composition for transdermal administration
HK1213638A1 (zh) * 2013-03-15 2016-07-08 University Of Miami 免疫增強藥物的納米載體
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
EP3038609B1 (en) * 2013-08-27 2021-07-28 Deutsches Krebsforschungszentrum Cytotoxic t cell response modifiers
US10744199B2 (en) * 2013-10-11 2020-08-18 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Epstein-Barr virus vaccines
WO2015116568A2 (en) * 2014-01-28 2015-08-06 University Of Miami Muscle cell-targeting nanoparticles for vaccination and nucleic acid delivery, and methods of production and use thereof
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP3324979B1 (en) 2015-07-21 2022-10-12 ModernaTX, Inc. Infectious disease vaccines
CA2999916C (en) * 2015-09-23 2021-07-20 Massachusetts Institute Of Technology Compositions and methods for modified dendrimer nanoparticle vaccine delivery
CA3002912A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
US20180289792A1 (en) 2015-10-22 2018-10-11 ModernaTX. Inc. Sexually transmitted disease vaccines
US20190184013A1 (en) * 2016-05-23 2019-06-20 University Of Miami Compositions for selective humoral responses and methods of use thereof
WO2017216768A1 (en) 2016-06-16 2017-12-21 Association For The Advancement Of Tissue Engineering And Cell Based Technologies And Therapies - A4Tec Dendrimer-derived artificial antigen, methods and uses thereof
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
WO2018151816A1 (en) * 2017-02-16 2018-08-23 Modernatx, Inc. High potency immunogenic compositions
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS Vaccine
WO2018237010A2 (en) * 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccine compositions and methods of using the same
RU2020103379A (ru) * 2017-07-04 2021-08-04 Куревак Аг Новые молекулы нуклеиновых кислот
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
EP3743526B1 (en) 2018-01-28 2025-03-12 Enable Biosciences Inc. Reagents and methods for blocking non-specific interactions with nucleic acids
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
TW202028222A (zh) * 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
CN110448695B (zh) * 2019-08-23 2021-07-27 中山大学肿瘤防治中心 一种mRNA疫苗递送载体及其制备方法
EP4308165A4 (en) * 2021-03-17 2026-04-08 Univ Northwestern Conjugated dendritic peptide polymers for efficient intracellular delivery of nucleic acids to immune cells
CN113173985A (zh) * 2021-03-24 2021-07-27 深圳市新靶向生物科技有限公司 一种与结直肠癌驱动基因突变相关的抗原肽及其应用
CN120209073B (zh) * 2025-05-28 2025-09-23 北京立康生命科技有限公司 一种有利于抗原呈递的间隔肽

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003A (en) * 1851-03-25 Improvement in scythe-tastenings
US3023A (en) * 1843-03-30 peters
US20050169900A1 (en) * 1993-02-17 2005-08-04 Sloan Kettering Institute For Cancer Research Allogeneic vaccine and methods to synthesize same
US6864060B1 (en) * 1993-03-31 2005-03-08 Cadus Technologies, Inc. Yeast cells expressing modified G proteins and methods of use therefor
AU698962B2 (en) * 1993-09-14 1998-11-12 Epimmune, Inc. Alteration of immune response using pan DR-binding peptides
CA2184132C (en) 1995-09-21 2011-03-15 Kristina J. Hennessy An adjuvanted vaccine which is substantially free of non-host albumin
US6204250B1 (en) * 1996-11-22 2001-03-20 The Mount Sinai Medical Center Of The City Of New York Immunization of infants
DE69834808T2 (de) * 1997-03-27 2007-06-06 Institut Pasteur Multiple,kohlenhydrathaltige glycopeptid-antigene, daraus entwickelte impfstoffe sowie deren verwendung
US6201250B1 (en) * 1997-08-22 2001-03-13 Richard C. Morlock Sensor housing for UV curing chamber
IL141868A0 (en) 1998-10-05 2002-03-10 M & E Biotech As Novel methods for therapeutic vaccination
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
US20040241842A1 (en) 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US6632435B1 (en) 1999-10-20 2003-10-14 City Of Hope CTL epitope analogs
EP1242049A4 (en) * 1999-12-13 2005-01-05 Epimmune Inc VACCINE COMPOSITIONS AND ANTIGEN PEPTIDES ASSOCIATED WITH CLASS I HLA-A2 TUMOR
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
CA2349506C (en) * 2001-06-14 2009-12-08 Duke University A method for selective expression of therapeutic genes by hyperthermia
EP1473564A4 (en) 2001-09-18 2008-12-10 Greenpeptide Co Ltd METHOD FOR DETECTING CELL IMMUNITY AND ITS APPLICATION TO MEDICAMENTS
CN1615316A (zh) * 2001-11-16 2005-05-11 法麦克萨有限公司 多聚体蛋白质的新免疫原性模拟物
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
AU2003208314A1 (en) 2002-03-11 2003-09-22 Pharmexa A/S Novel application of vaccination against tnf-alpha
US20080268457A1 (en) * 2002-11-14 2008-10-30 Dharmacon, Inc. siRNA targeting forkhead box P3 (FOXP3)
CN1809379A (zh) 2003-04-18 2006-07-26 诺伍德免疫学有限公司 先于胸腺再活化的疾病预防和疫苗接种
CN101506266A (zh) 2005-02-01 2009-08-12 梅迪沃什有限公司 疫苗输送组合物及使用方法
US7358231B1 (en) * 2005-12-01 2008-04-15 Applera Corporation Pancreatic cancer secreted targets and uses thereof
US8954355B2 (en) * 2006-01-26 2015-02-10 Psi Systems, Inc. Integrated postage and shipping label system
WO2007089607A2 (en) * 2006-01-26 2007-08-09 University Of Massachusetts Rna silencing agents for use in therapy and nanotransporters for efficient delivery of same
US9511134B2 (en) * 2006-05-18 2016-12-06 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
CN101711360A (zh) 2007-03-16 2010-05-19 赛乐思迪斯有限公司 细胞介导的免疫应答检验及其试剂盒
WO2008151389A1 (en) * 2007-06-15 2008-12-18 Macfarlane Burnet Institute For Medical Research And Public Health Limited Chemically modified macromolecules
RU2010107199A (ru) * 2007-07-31 2011-09-10 Дзе Джонс Хопкинс Юниверсити (Us) Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений
US9764012B2 (en) 2009-04-01 2017-09-19 University Of Miami Vaccine compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2012522802A5 (https=)
JP6321261B2 (ja) ワクチン組成物及びその使用方法
Hassan et al. Dual stimulation of antigen presenting cells using carbon nanotube-based vaccine delivery system for cancer immunotherapy
Skwarczynski et al. Recent advances in peptide-based subunit nanovaccines
Li et al. Rational design of polymeric hybrid micelles to overcome lymphatic and intracellular delivery barriers in cancer immunotherapy
Liu et al. Arginine-terminated generation 4 PAMAM dendrimer as an effective nanovector for functional siRNA delivery in vitro and in vivo
ES2754239T3 (es) Combinación de vacunación y agonistas de OX40
Tanaka et al. Cytoplasm-responsive nanocarriers conjugated with a functional cell-penetrating peptide for systemic siRNA delivery
Tambe et al. Triptorelin tethered multifunctional PAMAM-histidine-PEG nanoconstructs enable specific targeting and efficient gene silencing in LHRH overexpressing cancer cells
JP2012521201A5 (https=)
Zhang et al. Sulfonium-driven neoantigen-released DNA nanodevice as a precise vaccine for tumor immunotherapy and prevention
JP2015529678A5 (https=)
Avila et al. Gene delivery and immunomodulatory effects of plasmid DNA associated with Branched Amphiphilic Peptide Capsules
EP3630807A1 (en) Pd-1 and ctla-4 dual inhibitor peptides
JP2015533376A5 (https=)
Huang et al. Modularized viromimetic polymer nanoparticle vaccines (VPNVaxs) to elicit durable and effective humoral immune responses
De Lombaerde et al. Combinatorial screening of biscarbamate ionizable lipids identifies a low reactogenicity lipid for lipid nanoparticle mRNA delivery
JP2014502961A5 (https=)
Demircan et al. Biotin functionalized self‐assembled peptide nanofiber as an adjuvant for immunomodulatory response
US20230293448A1 (en) Nanoparticle immunogenic compositions and vaccination methods
JP2022517236A (ja) 自己組織化ペプチドナノ粒子およびその使用
Wang et al. Spatiotemporal Nano‐Regulator Unleashes Anti‐Tumor Immunity by Overcoming Dendritic Cell Tolerance and T Cell Exhaustion in Tumor‐Draining Lymph Nodes
Hong et al. An mRNA vaccine against SARS-CoV-2: Lyophilized, liposome-based vaccine candidate EG-COVID induces high levels of virus neutralizing antibodies
Brubaker et al. A cationic micelle complex improves CD8+ T cell responses in vaccination against unmodified protein antigen
Kang et al. Self-assembled nanoparticles based on DNA origami and a nitrated T helper cell epitope as a platform for the development of personalized cancer vaccines